Back Tuberculosis

WHO: TB Rates Fall, but Drug Resistance Still a Concern

Rates of new tuberculosis (TB) cases and deaths have declined and approximately 20 million people worldwide are alive due to TB care and control efforts, but too little is being done to address multidrug-resistant TB, according to the World Health Organization's Global Tuberculosis Report 2012.alt

Read more:

Adding Delamanid to Combination Regimen Reduces Risk of Death for People with Resistant TB

The novel investigational tuberculosis (TB) drug delamanid, when added to an optimized combination regimen, significantly reduced mortality among patients with multidrug-resistant TB, according to a study published in the September 27, 2012, advance edition of the European Respiratory Journal.

Read more:

ICAAC 2012: Experimental Nitroimidazole TBA-354 Shows Promise against Tuberculosis in Early Studies

The experimental nitroimidazole TBA-354, under investigation by the TB Alliance, showed potent activity against Mycobacterium tuberculosis in vitro and in animal studies, according to a presentation this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. alt

Read more:

Study Shows Extensively Drug-resistant TB is Becoming More Common Worldwide

More than 40% of people with multidrug-resistant pulmonary tuberculosis in a multi-country study were found to be resistant to at least 1 second-line anti-tuberculosis agent and 7% had extensively drug-resistant disease, researchers reported in the August 29, 2012, advance online edition of The Lancet.

Read more:

AIDS 2012: No Interactions Seen Between New TB Drug and Popular HIV Meds

The promising experimental tuberculosis (TB) drug delamanid does not interact with the widely used antiretrovirals tenofovir (Viread) and lopinavir/ritonavir (Kaletra) in ways likely to cause clinical problems, researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.

Read more: